The global Preimplantation Genetic Diagnosis Market is estimated to be valued at US$ 64.08 Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Preimplantation genetic diagnosis (PGD) is a medical procedure that involves testing embryos for genetic diseases before implantation and pregnancy. It allows identification of genetic defects in embryos created through in vitro fertilization (IVF) to select unaffected embryos for implantation. PGD is useful for couples with a family history of genetic disorders or chromosomal abnormalities in order to have healthier children.
Market key trends:
One of the key trends fueling the growth of preimplantation genetic diagnosis market is the increasing use of PGD for multiple genetic assessments in a single IVF cycle. Traditionally, PGD was used to test for a single genetic condition. However, with advancement in technologies like next-generation sequencing, multiple genetic tests can now be performed during a single IVF cycle. This has increased the efficiency and affordability of PGD procedures. Moreover, the advent of technologies like array comparative genomic hybridization has enabled comprehensive screening of entire genomes of embryos for abnormalities. This is helping to identify more genetic defects.
The preimplantation genetic diagnosis market is segmented based on application, technology, end-user and region. By application, the aneuploidy screening segment held the largest market share in 2022 owing to increasing prevalence of aneuploidy defects such as Down syndrome during IVF. By technology, the next generation sequencing (NGS) segment is dominating the market due to rise in affordability and accuracy of NGS over other technologies. By end user, fertility clinics are dominating the market as these clinics perform majority of IVF cycles and PGD tests.
The global Preimplantation Genetic Diagnosis Market Growth is expected to witness high growth, exhibiting CAGR of 6.2% over the forecast period, due to increasing incidence of genetic abnormalities and growth in popularity of IVF treatment.
Regionally, North America currently dominates the PGD market owing to high adoption of advanced reproductive technologies and presence of major market players in the region. Asia Pacific region is expected to grow at the fastest pace during the forecast period due to rising fertility tourism, increasing healthcare expenditures and growing medical tourism industry.
The global preimplantation genetic diagnosis market size is projected to reach US$ 64.08 Mn in 2023. Key players operating in the preimplantation genetic diagnosis market are Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., and Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.